价格管制、医保支付政策与制药企业创新激励

科研管理 ›› 2015, Vol. 36 ›› Issue (12): 120-128.

价格管制、医保支付政策与制药企业创新激励

张新鑫^1,2, 侯文华², 申成霖³

1. 天津理工大学管理学院, 天津 300384;
2. 南开大学商学院, 天津 300071;
3. 天津工业大学管理学院, 天津 300387

收稿日期:2014-01-17 修回日期:2015-04-07 出版日期:2015-12-25 发布日期:2015-12-22
作者简介:侯文华(1964-),男(汉),河北邢台人,教授、博士研究生导师。研究方向:创新管理,决策与对策理论等。
张新鑫(1980-),女(锡伯族),河北邯郸人,博士,讲师。研究方向:创新与运营管理。
申成霖(1975-),男(汉),山东莒县人,博士后,副教授。研究方向:创新及运营管理,营销科学。
基金资助:
国家社会科学基金(15BGL074,2015.06-2018.12);国家自然科学基金(71071080, 2011.01-2014.12)。

Price regulation, medicare payment policy and pharmaceutical firm's innovation incentives

Zhang Xinnxin^1,2, Hou Wenhua², Shen Chenglin³

1. School of Management, Tianjin University of Technology, Tianjin 300384, China;
2. School of Business, Nankai University, Tianjin 300071, China;
3. School of Management, Tianjin Polytechnic University, Tianjin 300387, China

Received:2014-01-17 Revised:2015-04-07 Online:2015-12-25 Published:2015-12-22

摘要/Abstract

摘要： 本文综合考虑价格管制和现行的医保支付政策,研究制药企业创新投入和药品定价的协同决策问题,探讨价格管制和医保支付政策对制药企业创新投入和创新药定价的交互作用机制。研究表明,制药企业定价机制的选择受到管制价格和医保支付政策的双重影响,特别地,当医保支付比例较高时,价格不能作为药品的创新水平的信号,适当降低医保支付有助于控制制药企业创新中的机会主义行为;价格管制对制药企业创新投入的作用受到医保支付政策和企业自身创新能力的共同影响;价格管制并非总是降低企业的创新激励,当医保支付比例较高时,价格管制可在一定程度上纠正创新投入配置的扭曲,提高创新能力中等的制药企业的创新激励。

关键词: 价格管制, 医保支付政策, 创新投入, 定价机制, 制药企业

Abstract: This paper studies collaborative decisions on innovation investment and pricing of a pharmaceutical firm in a complete competitive market, considering price regulation and medicare policy simultaneously. We explore interactions between price regulation and medicare payment on the firm's innovation investment and pricing mechanisms. The results are as follows:first, new medicine's pricing mechanisms are determined by the ceiling price and the medicare policy jointly, especially the price of the new medicine is not able to indicate its innovation level if the medicare payment is low; second, lowering the medicare payment appropriately will reduce the firm's opportunistic behavior in innovation; third, impacts of price regulation on pharmaceutical firm's innovation investment are influenced by the medicare policy and firm's own innovation ability collectively; and finally, price regulation does not necessarily result in innovation underinvestment and it might correct the distortion of innovation investment allocation and enhance innovation investment of the pharmaceutical firm with medium innovation ability if the medicare payment is high.

Key words: price regulation, medicare policy, innovation investment, pricing mechanism, pharmaceutical firms

中图分类号:

F270-05

张新鑫, 侯文华, 申成霖. 价格管制、医保支付政策与制药企业创新激励[J]. 科研管理, 2015, 36(12): 120-128.

Zhang Xinnxin, Hou Wenhua, Shen Chenglin. Price regulation, medicare payment policy and pharmaceutical firm's innovation incentives[J]. Science Research Management, 2015, 36(12): 120-128.

参考文献

[1] Barry J, Loehr J, Holman R. The global innovation 1000:Navigating the digital future[R]. Booz & Company. 2013. [2] 赵远亮,周寄中,侯亮,许治.医药企业知识产权与经营绩效的关联性研究[J].科研管理, 2009, 30(4):175-183.Zhao Yuanliang, Zhou Jizhong, Hou Liang, Xu Zhi. An empirical research on the relation between pharmaceutical listed company's intellectual property fight and its performance[J]. Science Research Management, 2009, 30(4):175-183. [3] United states government accountability office. New drug development:Science, business, regulatory and intellectual property issues cited as hampering drug development efforts[R]. 2006, http://www.gao.gov./new.Items/do749.pdf. [4] 中国药品食品监督管理局. 2012年药品注册审批年度报告[R]. 2013, http://www.cde.org.cn.SFDA. The annual report for examination and approval of drug registration in 2012[R]. 2013, http://www.cde.org.cn. [5] Henry D, Lexchin J. The Pharmaceutical industry as a medicines provider[J]. Medicines society and industry Ⅲ, 2002, (360):590-1595. [6] Amaldoss W, He C. Direct-to-consumer advertising of prescription drugs:A strategic analysis[J]. Marketing Science, 2009, 28(3):472-487. [7] Ganuza J, Llobet G, Dominguez B.R&D in the pharmaceutical industry:A world of small innovation[J]. Management Science, 2009, 55(4):539-551. [8] Scherer F. The pharmaceutical industry[M]. Handbook of Health Economics, vol. 1. Amsterdam:Elsevier, 2000, 1297-1336. [9] 陈文.我国药品价格管制的政策选择[J].中国卫生政策研究,2008, 1(3):35-38.Chen Wen.Policy options for pharmaceutical price regulation[J]. Chinese journal of health policy, 2008, 1(3):35-38. [10] Vernon J A. Examining the link between price regulation and pharmaceutical R&D investment[J]. Health Economics, 2005, (14):1-16. [11] 唐艳,徐怀伏.药品价格管制与社会福利的经济学分析[J].中国卫生经济,2008, 27(7):52-54.Tang Yan, Xu Huaifu. Economic analysis of pharmaceutical price regulation and social welfare[J]. Chinese Health Economics, 2008, 27(7):52-54. [12] Bardey, D.Bommier, A. and Jullien, B. Retail price regulation and innovation:Reference pricing in the pharmaceutical industry[J]. Journal of Health Economies, 2010, (29):303-316. [13] Besanko D, Donnenfeld S, White L. The multiproduct firm, quality choice, and regulation[J]. Journal of Industrial Economics, 1988, 36(4):411-429. [14] Armstrong M, Vickers J. Welfare effects of price discrimination by a regulated monopolist[J]. Rand Journal of Economics, 1991, 22(4):571-580. [15] 刘小鲁.产品多样化、产品质量与中国药品价格管制绩效[J].经济评论, 2010(6):76-84.Liu Xiaolu. Diversification, product quality and performances of price ceiling in China's pharmaceutical industry[J]. Economic Review, 2010(6):76-84. [16] Grossmann V. Do cost-sharing and entryderegulation curb pharmaceutical innovation?[J]. Journal of Health Economics, 2013(32):881-894. [17] 杜创.药品流通与定价的理性与复杂[J].中国医院院长, 2013(3):112-113.Du Chuang. Rationality and complex in circulation and pricing of drugs[J]. China Hospital CEO, 2013(3):112-113. [18] Milgrom P R, Shannon C. Monotone comparative statics[J]. Econometrica, 1994, 62(1):157-180.